TABLE 2.

Univariate analysis for progression-free survival.

Factors	Univariate analysis
	Median PFS (95% CI)	P value
Age ≥60 years	18.90 (15.12–22.68)	0.885
Age <60 years	19.70 (16.24–23.16)
Hemoglobin ≤100 g/L	17.90 (14.03–21.50)	0.481
Hemoglobin >100 g/L	22.67 (16.33–29.01)
Serum creatinine ≥177 μmmol/L	19.87 (12.83–26.91)	0.271
Serum creatinine <177 μmmol/L	19.40 (16.28–22.52)
Albumin <35 g/L	19.70 (15.86–23.55)	0.841
Albumin ≥35 g/L	19.30 (16.30–22.30)
β2-microglobulin <3.5 g/L	23.93 (17.39–30.47)	0.089
β2-microglobulin ≥3.5 g/L	17.90 (14.03–21.77)
≥VGPR	20.77 (15.66–25.88)	0.012
<VGPR	16.90 (13.95–19.85)
ISS Stage I	24.60 (16.07–33.13)	0.232
ISS Stage II	17.90 (13.71–22.09)
ISS Stage III	19.40 (15.03–23.78)
LDH (<240 IU/L)	19.70 (16.48–22.92)	0.572
LDH (≥240 IU/L)	17.37 (10.08–24.66)
High risk cytogenetics	14.90 (10.93–18.87)	0.011
Non- high risk cytogenetics	19.97 (16.82–23.12)
NMLR <1.90	24.00 (15.44–32.50)	0.002
NMLR ≥1.90	15.50 (11.57–19.43)

Abbreviations: LDH: lactate dehydrogenase; VGPR, very good partial response; ISS, international staging system; NMLR, (neutrophil + monocytes) to lymphocytes ratio.